title: Muraglitazar-eluting bioabsorbable vascular stent inhibits neointimal hyperplasia in porcine iliac arteries.
abstract: OBJECTIVE
  To evaluate the biocompatibility of a new muraglitazar-eluting polylactide copolymer stent and investigate its ability to prevent the formation of intimal hyperplasia.
  
  
  METHODS
  Ten self-expandable muraglitazar-eluting poly-96 L/4D-lactic acid (PLA96) stents and 10 self-expandable control PLA96 stents were implanted into porcine common iliac arteries. After 28 days follow-up, all stent-implanted iliac arteries were harvested and prepared for quantitative histomorphometric analysis.
  
  
  RESULTS
  Angiographic analysis revealed that one control PLA96 stent had occluded and one had migrated. Histomorphometric analysis demonstrated that, with the control PLA96 stent, the luminal diameter and area were decreased versus the muraglitazar-eluting PLA96 stents (means ± standard error of the mean, 3.58 mm ± 0.34 vs 4.16 mm ± 0.14 and 9.83 mm(2) ± 2.41 vs 13.75 mm(2) ± 0.93, respectively). The control PLA96 stent induced more intimal hyperplasia than the bioactive muraglitazar-eluting PLA96 stent (557 µm ± 122 vs 361 µm ± 32). Vascular injury scores demonstrated only mild vascular trauma for both stents (muraglitazar-eluting, 0.68 ± 0.07; control, 0.75 ± 0.08). Inflammation scores also showed mild inflammation for both stents (muraglitazar-eluting, 1.05 ± 0.17; control, 1.23 ± 0.19).
  
  
  CONCLUSIONS
  This new muraglitazar-eluting PLA96 stent was shown to be biocompatible with a tendency for better patency and less intimal hyperplasia compared with the control PLA96 stents.
authors.affiliation: Divisions of Vascular Surgery and Urology, Department of Surgery, Tampere University Hospital, Tampere, Finland. Electronic address: ilkka.uurto@uta.fi.
authors.forename: Ilkka
authors.initials: I
authors.lastname: Uurto
authors.affiliation: Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland.
authors.forename: Mari
authors.initials: M
authors.lastname: Hämäläinen
authors.affiliation: Divisions of Vascular Surgery and Urology, Department of Surgery, Tampere University Hospital, Tampere, Finland.
authors.forename: Velipekka
authors.initials: V
authors.lastname: Suominen
authors.affiliation: Department of Pathology, Tampere University Hospital, Tampere, Finland.
authors.forename: Marita
authors.initials: M
authors.lastname: Laurila
authors.affiliation: Divisions of Vascular Surgery and Urology, Department of Surgery, Tampere University Hospital, Tampere, Finland.
authors.forename: Andres
authors.initials: A
authors.lastname: Kotsar
authors.affiliation: Department of Surgery, Päijät-Häme Central Hospital, Lahti, Finland.
authors.forename: Taina
authors.initials: T
authors.lastname: Isotalo
authors.affiliation: Divisions of Vascular Surgery and Urology, Department of Surgery, Tampere University Hospital, Tampere, Finland.
authors.forename: Teuvo L J
authors.initials: TL
authors.lastname: Tammela
authors.affiliation: Biomaterials and Tissue Engineering Group, Department of Electronics and Communications Engineering, Tampere University of Technology, Tampere, Finland; BioMediTech-Institute of Biosciences and Medical Technology, Tampere, Finland.
authors.forename: Minna
authors.initials: M
authors.lastname: Kellomäki
authors.affiliation: Divisions of Vascular Surgery and Urology, Department of Surgery, Tampere University Hospital, Tampere, Finland.
authors.forename: Juha-Pekka
authors.initials: JP
authors.lastname: Salenius
mesh_terms: D000818:Animals; D020099:Coated Materials, Biocompatible; D054855:Drug-Eluting Stents; D005998:Glycine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006965:Hyperplasia / Q000517:prevention & control; D007083:Iliac Artery / Q000473:pathology* / Q000601:surgery*; D010080:Oxazoles / Q000627:therapeutic use*; D013552:Swine; D017539:Tunica Intima / Q000473:pathology*
chemical_list: D020099:Coated Materials, Biocompatible; D010080:Oxazoles; D005998:Glycine; C500085:muraglitazar